Intuitive Surgical's Growth Has Cooled From Its Post-Pandemic Highs. Is That a Buying Opportunity or a Warning?

Intuitive Surgical (ISRG) is trading about 40% below recent highs amid a long history of sharp drawdowns (eight declines of 30%+; two of 70%+). While new da Vinci robot placements rose to 468 in Q2 2026 vs 395 in Q2 2025, the key growth metric—surgeries performed with da Vinci robots—rose 16% YoY even as the installed base grew 12%, underscoring a maturing but still durable services/parts “flywheel” (roughly 75% of Q2 sales from parts/services vs ~24% from new robot sales). The article argues AI-assisted surgery and parts/services annuity-like income provide longer-run upside, but near-term growth is pressured by intensifying competition from large medical device players.

Analysis

The market is still pricing this like a hardware story, but the real economic engine is the installed base. That matters because new-system placement can slow materially before the equity thesis fully breaks; the recurring parts/service stream should smooth revenue and support margin longer than headline unit growth implies. In the near term, competition from large medtech incumbents is most likely to pressure sentiment and the multiple, not instantly displace the platform.

The second-order risk is that competitive launches force heavier R&D and commercial spending just as system sales become less predictable, which can compress operating leverage even if procedure volume keeps rising. Over 1-3 months, the key catalyst is whether the next print shows procedure growth still outpacing installed-base growth; if that gap narrows, the market will likely conclude the annuity model is maturing faster than expected. Over 6-18 months, the true issue is share of future procedures, not share of robot placements.

Consensus may be underweighting how sticky the base is and overweighting the importance of new robot sales, but it may also be overestimating AI as a near-term monetization driver. AI-enabled autonomous surgery is a years-out option, not a quarter-to-quarter catalyst, so it should not anchor valuation support today. The thesis breaks if recurring consumables growth decelerates into the high single digits or if a competitor proves it can convert hospital evaluations into sustained utilization at scale.

Key Decisions for Investors

• Do not short ISRG purely on the placement slowdown; the better expression is a wait-and-see alert for a 1-2 quarter deterioration in procedure growth or instrument/consumables growth before pressing downside.
• For investors who want exposure, prefer a 6-12 month ISRG bull call spread over stock to limit volatility risk; use a pullback as entry only if procedure growth remains double-digit.
• Relative-value watch: short ISRG vs long MDT or JNJ only if upcoming product disclosures show credible competitive traction; otherwise competition is more narrative than earnings-impacting.
• Set a falsifier on ISRG: if recurring revenue growth falls below high-single digits or procedure growth drops into the low teens, expect multiple compression and reassess long exposure.